121 related articles for article (PubMed ID: 21567093)
1. A new molecular targeted therapeutic approach for renal cell carcinoma with a p16 functional peptide using a novel transporter system.
Zennami K; Yoshikawa K; Kondo E; Nakamura K; Upsilonamada Y; De Velasco MA; Tanaka M; Uemura H; Shimazui T; Akaza H; Saga S; Ueda R; Honda N
Oncol Rep; 2011 Aug; 26(2):327-33. PubMed ID: 21567093
[TBL] [Abstract][Full Text] [Related]
2. Potent synergy of dual antitumor peptides for growth suppression of human glioblastoma cell lines.
Kondo E; Tanaka T; Miyake T; Ichikawa T; Hirai M; Adachi M; Yoshikawa K; Ichimura K; Ohara N; Moriwaki A; Date I; Ueda R; Yoshino T
Mol Cancer Ther; 2008 Jun; 7(6):1461-71. PubMed ID: 18566217
[TBL] [Abstract][Full Text] [Related]
3. Molecular targeting of neuroblastoma with a novel p16INK4a transporter system.
Kawaguchi T; Yoshikawa K; Kawamoto K; Yoshimura K; Oshige H; Asai A
Int J Oncol; 2014 Jun; 44(6):1879-85. PubMed ID: 24714808
[TBL] [Abstract][Full Text] [Related]
4. Pretargeting with bispecific anti-renal cell carcinoma x anti-DTPA(In) antibody in 3 RCC models.
van Schaijk FG; Oosterwijk E; Molkenboer-Kuenen JD; Soede AC; McBride BJ; Goldenberg DM; Oyen WJ; Corstens FH; Boerman OC
J Nucl Med; 2005 Mar; 46(3):495-501. PubMed ID: 15750164
[TBL] [Abstract][Full Text] [Related]
5. Targeted therapy of experimental renal cell carcinoma with a novel conjugate of monoclonal antibody 138H11 and calicheamicin thetaI1.
Knoll K; Wrasidlo W; Scherberich JE; Gaedicke G; Fischer P
Cancer Res; 2000 Nov; 60(21):6089-94. PubMed ID: 11085532
[TBL] [Abstract][Full Text] [Related]
6. Anti-CD26 monoclonal antibody-mediated G1-S arrest of human renal clear cell carcinoma Caki-2 is associated with retinoblastoma substrate dephosphorylation, cyclin-dependent kinase 2 reduction, p27(kip1) enhancement, and disruption of binding to the extracellular matrix.
Inamoto T; Yamochi T; Ohnuma K; Iwata S; Kina S; Inamoto S; Tachibana M; Katsuoka Y; Dang NH; Morimoto C
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3470-7. PubMed ID: 16740772
[TBL] [Abstract][Full Text] [Related]
7. Trojan p16 peptide suppresses pancreatic cancer growth and prolongs survival in mice.
Hosotani R; Miyamoto Y; Fujimoto K; Doi R; Otaka A; Fujii N; Imamura M
Clin Cancer Res; 2002 Apr; 8(4):1271-6. PubMed ID: 11948142
[TBL] [Abstract][Full Text] [Related]
8. Potent antitumor activity of a novel nucleoside analogue, BCH-4556 (beta-L-dioxolane-cytidine), in human renal cell carcinoma xenograft tumor models.
Kadhim SA; Bowlin TL; Waud WR; Angers EG; Bibeau L; DeMuys JM; Bednarski K; Cimpoia A; Attardo G
Cancer Res; 1997 Nov; 57(21):4803-10. PubMed ID: 9354442
[TBL] [Abstract][Full Text] [Related]
9. In vitro and in vivo tumor growth inhibition by a p16-mimicking peptide in p16INK4A-defective, pRb-positive human melanoma cells.
Noonan DM; Severino A; Morini M; Tritarelli A; Manente L; D'Agnano I; Starace G; Baldi A; Lombardi D; Albini A; Felsani A; Paggi MG
J Cell Physiol; 2005 Mar; 202(3):922-8. PubMed ID: 15389561
[TBL] [Abstract][Full Text] [Related]
10. Receptors for luteinizing hormone releasing hormone expressed on human renal cell carcinomas can be used for targeted chemotherapy with cytotoxic luteinizing hormone releasing hormone analogues.
Keller G; Schally AV; Gaiser T; Nagy A; Baker B; Halmos G; Engel JB
Clin Cancer Res; 2005 Aug; 11(15):5549-57. PubMed ID: 16061872
[TBL] [Abstract][Full Text] [Related]
11. Blockade of epidermal growth factor receptor signaling leads to inhibition of renal cell carcinoma growth in the bone of nude mice.
Weber KL; Doucet M; Price JE; Baker C; Kim SJ; Fidler IJ
Cancer Res; 2003 Jun; 63(11):2940-7. PubMed ID: 12782601
[TBL] [Abstract][Full Text] [Related]
12. Combined gene expression profiling and RNAi screening in clear cell renal cell carcinoma identify PLK1 and other therapeutic kinase targets.
Ding Y; Huang D; Zhang Z; Smith J; Petillo D; Looyenga BD; Feenstra K; Mackeigan JP; Furge KA; Teh BT
Cancer Res; 2011 Aug; 71(15):5225-34. PubMed ID: 21642374
[TBL] [Abstract][Full Text] [Related]
13. Systemic transduction of p16INK4A antitumor peptide inhibits the growth of MBT-2 mouse bladder tumor cell line grafts.
Shimazui T; Yoshikawa K; Miyazaki J; Kojima T; Inai H; Ando S; Uemura H; Uchida K; Nishiyama H
Int J Oncol; 2013 Feb; 42(2):543-8. PubMed ID: 23292502
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of DLC-1 induces cell apoptosis and proliferation inhibition in the renal cell carcinoma.
Zhang T; Zheng J; Jiang N; Wang G; Shi Q; Liu C; Lu Y
Cancer Lett; 2009 Sep; 283(1):59-67. PubMed ID: 19380190
[TBL] [Abstract][Full Text] [Related]
15. Connexin 32 potentiates vinblastine-induced cytotoxicity in renal cell carcinoma cells.
Sato H; Senba H; Virgona N; Fukumoto K; Ishida T; Hagiwara H; Negishi E; Ueno K; Yamasaki H; Yano T
Mol Carcinog; 2007 Mar; 46(3):215-24. PubMed ID: 17186540
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of nuclear factor kappa B attenuates tumour progression in an animal model of renal cell carcinoma.
Morais C; Healy H; Johnson DW; Gobe G
Nephrol Dial Transplant; 2010 May; 25(5):1462-74. PubMed ID: 20037166
[TBL] [Abstract][Full Text] [Related]
17. Residualizing iodine markedly improved tumor targeting using bispecific antibody-based pretargeting.
van Schaijk FG; Broekema M; Oosterwijk E; van Eerd JE; McBride BJ; Goldenberg DM; Corstens FH; Boerman OC
J Nucl Med; 2005 Jun; 46(6):1016-22. PubMed ID: 15937314
[TBL] [Abstract][Full Text] [Related]
18. A flavivirus protein M-derived peptide directly permeabilizes mitochondrial membranes, triggers cell death and reduces human tumor growth in nude mice.
Brabant M; Baux L; Casimir R; Briand JP; Chaloin O; Porceddu M; Buron N; Chauvier D; Lassalle M; Lecoeur H; Langonné A; Dupont S; Déas O; Brenner C; Rebouillat D; Muller S; Borgne-Sanchez A; Jacotot E
Apoptosis; 2009 Oct; 14(10):1190-203. PubMed ID: 19693674
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of both mesothelioma cell growth and Cdk4 activity following treatment with a TATp16INK4a peptide.
Frizelle SP; Kratzke MG; Carreon RR; Engel SC; Youngquist L; Klein MA; Fourre L; Shekels LL; Kratzke RA
Anticancer Res; 2008; 28(1A):1-7. PubMed ID: 18383817
[TBL] [Abstract][Full Text] [Related]
20. Dual degradation of aurora A and B kinases by the histone deacetylase inhibitor LBH589 induces G2-M arrest and apoptosis of renal cancer cells.
Cha TL; Chuang MJ; Wu ST; Sun GH; Chang SY; Yu DS; Huang SM; Huan SK; Cheng TC; Chen TT; Fan PL; Hsiao PW
Clin Cancer Res; 2009 Feb; 15(3):840-50. PubMed ID: 19188154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
